MEDNAX Inc (MD) Given Consensus Recommendation of “Hold” by Brokerages
MEDNAX Inc (NYSE:MD) has received a consensus rating of “Hold” from the seventeen ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eleven have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $54.00.
A number of research firms recently commented on MD. Zacks Investment Research lowered shares of MEDNAX from a “hold” rating to a “sell” rating in a research report on Tuesday, July 3rd. Leerink Swann began coverage on shares of MEDNAX in a research report on Thursday, July 12th. They set a “market perform” rating and a $50.00 price target on the stock. Stifel Nicolaus set a $47.00 price target on shares of MEDNAX and gave the stock a “hold” rating in a research report on Thursday, August 2nd. Credit Suisse Group raised shares of MEDNAX from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $47.00 to $55.00 in a research report on Friday, August 3rd. Finally, ValuEngine raised shares of MEDNAX from a “strong sell” rating to a “sell” rating in a research report on Friday, August 3rd.
Shares of NYSE MD traded up $0.36 during mid-day trading on Friday, reaching $47.57. 18,306 shares of the company were exchanged, compared to its average volume of 483,267. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.52 and a current ratio of 1.52. The stock has a market cap of $4.43 billion, a PE ratio of 14.99, a P/E/G ratio of 1.30 and a beta of 0.24. MEDNAX has a twelve month low of $40.56 and a twelve month high of $63.04.
In other MEDNAX news, insider John C. Pepia sold 3,500 shares of the firm’s stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $48.18, for a total value of $168,630.00. Following the transaction, the insider now directly owns 30,148 shares of the company’s stock, valued at approximately $1,452,530.64. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 2.40% of the stock is owned by company insiders.
Hedge funds have recently added to or reduced their stakes in the business. Summit Trail Advisors LLC grew its holdings in shares of MEDNAX by 2,817.3% during the 1st quarter. Summit Trail Advisors LLC now owns 103,564 shares of the company’s stock valued at $104,000 after purchasing an additional 100,014 shares during the last quarter. Point72 Hong Kong Ltd bought a new stake in shares of MEDNAX during the 2nd quarter valued at approximately $172,000. Blair William & Co. IL bought a new stake in shares of MEDNAX during the 1st quarter valued at approximately $211,000. NumerixS Investment Technologies Inc grew its holdings in shares of MEDNAX by 147.8% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 5,700 shares of the company’s stock valued at $247,000 after purchasing an additional 3,400 shares during the last quarter. Finally, Unison Advisors LLC bought a new stake in shares of MEDNAX during the 2nd quarter valued at approximately $274,000. 95.50% of the stock is currently owned by hedge funds and other institutional investors.
MEDNAX Company Profile
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.
Further Reading: Day Trading – Risk Worth the Reward?
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.